Previous close | 61.21 |
Open | 61.28 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 61.22 - 61.82 |
52-week range | 49.44 - 63.98 |
Volume | |
Avg. volume | 2,632,738 |
Market cap | 70.265B |
Beta (5Y monthly) | 1.61 |
PE ratio (TTM) | 10.03 |
EPS (TTM) | 6.12 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 4.60 (7.52%) |
Ex-dividend date | 21 May 2024 |
1y target est | 73.00 |
BNP Paribas share buyback programme Declaration of transactions in own sharesfrom March 11, 2024 to March 15, 2024 Press releaseParis, 18 March 2024 In accordance with Article 5 of Regulation (EU) No 596/2014 on Market Abuse and Article 3 (3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programs and stabilization measures, BNP Paribas informs the market of the following tran
(Bloomberg) -- BNP Paribas SA is considering a potential acquisition of Fosun International Ltd.’s stake in Belgian insurer Ageas, according to people with knowledge of the matter. Most Read from BloombergA $2 Billion Airport Will Test Modi’s Mission, Adani’s AmbitionsFed Seen Sticking With Three 2024 Cuts Despite Higher InflationBitcoin Extends Retreat From Record as ‘Bubble’ Talk EscalatesApple Buys Canadian AI Startup as It Races to Add FeaturesS&P 500 Falls as $5.3 Trillion Options Test Loom
Skincare company Galderma was on course to raise 2.3 billion ($2.6 billion) Swiss francs from its upcoming initial public (IPO) offering after a positive response from potential investors. The company, whose products includes Cetaphil, a product for damaged and sensitive skin, as well as fillers and skin creams, early on Wednesday announced a price range of 49 to 53 Swiss francs for its flotation - likely to be one of the biggest in Europe this year. The offering consists of up to 40.5 million new shares and 277,000 existing shares, the company said.